CHI`s Optimizing Bioassays for Biologics 2013 is a conference that covers topics such as:
- New Technologies and Approaches to Bioassays
- Optimizing Bioassays for Biologics
- Development and Optimization of a Potency Assay for a 7 Component Peptide Drug
- Optimization of Ligand Binding Assay by Design of Experiment
- A Regulatory Perspective on Bioassays for Evaluation of the Quality of Protein Drug Products
- Reference Standards for Potency Assays – Future Directions
- A Statistical Approach to Bioassay Bridging and Transfer
- Compendial Potency Assays and Associated Biological Reference Materials – Challenges in Assay Transition and Unit Maintenance
- Evaluation of Processes for Reducing and Monitoring Assay Variability for Bioassays
- Regulatory-Compliant Validation of a Standardized ADCC Potency Assay
- Assay Development, Automation and De-Convolution of Multiplexed High Throughput Live-Cell Screens
- Bioluminescent NFAT-RE-luciferase Reporter Bioassay: A Novel Technology to Reduce Assay Variability in ADCC
- Functional Assays for Biosimilars: An Industry Perspective
- Special Considerations for Developing Cell-Based Immunogenicity Neutralizing Anti-Drug Antibody (NAb) Assays to Support Clinical Comparability Studies for Biosimilars
- Characterization Using a Surrogate Non Cell-Based Ligand Binding Assay
- Comparison of Cell-Based and Non Cell-Based Assay Platforms for the Detection of Anti-Drug Neutralizing Antibodies
CHI`s Optimizing Bioassays for Biologics 2013 brings together attendess involved in
- Cell and antibody engineering
- Bioanalytical R&D
- Pharmacology
- Immunology
- Preclinical and clinical development
